Skip to main content

Peer Review reports

From: Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

Original Submission
24 Sep 2018 Submitted Original manuscript
16 Dec 2018 Reviewed Reviewer Report - Shigenori Kadowaki
2 Jan 2019 Reviewed Reviewer Report - Lorenzo Ferri
12 Jan 2019 Reviewed Reviewer Report - Satoru Iwasa
8 Feb 2019 Author responded Author comments - Maria Di Bartolomeo
Resubmission - Version 2
8 Feb 2019 Submitted Manuscript version 2
27 Feb 2019 Reviewed Reviewer Report - Satoru Iwasa
7 Mar 2019 Author responded Author comments - Maria Di Bartolomeo
Resubmission - Version 3
7 Mar 2019 Submitted Manuscript version 3
15 Mar 2019 Author responded Author comments - Maria Di Bartolomeo
Resubmission - Version 4
15 Mar 2019 Submitted Manuscript version 4
Publishing
20 Mar 2019 Editorially accepted
29 Mar 2019 Article published 10.1186/s12885-019-5498-3

You can find further information about peer review here.

Back to article page